<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-06-03-2026-shutterstock_524659801-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-06-03-2026-shutterstock_524659801-430x241.jpg"/>
                                    
                                    <figcaption>With optimised CAR-sequence intellectual property and cell-selective LNP technology, Liberate Bio can advance in vivo CAR-M therapies. Credit: sirtravelalot / Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Liberate Bio has obtained both exclusive and non-exclusive licences for patents related to chimeric antigen receptor (CAR) designs tailored for myeloid cells, such as monocytes and macrophages.</p>



<p>The licences sourced from Carisma Therapeutics and the University of Pennsylvania include methods and constructs specifically engineered for function within these immune cell populations.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Idecabtagene Vicleucel in Multiple Myeloma (Ka... </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Lisocabtagene Maraleucel in Chronic Lymphocyti... </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>The designs complement Liberate Bio’s lipid nanoparticle (LNP) delivery platform, which enables the selective programming of macrophages and monocytes in vivo.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>With both the optimised CAR-sequence intellectual property and its cell-selective LNP technology, Liberate Bio is now positioned to advance in vivo CAR-M therapies into clinical assessment.</p>



<p>Liberate Bio’s Raptor platform conducts direct screening of LNPs in non-human primates to discover delivery vehicles aimed at extrahepatic immune cells.</p>



<p>The company has previously disclosed that its lead LNP resulted in more than 99% depletion of circulating B cells in non-human primates by selectively programming monocytes and macrophages.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>Liberate Bio’s chief scientific officer Walter Strapps said: “This licensing agreement meaningfully strengthens our clinical programmes. Myeloid cells have unique biology distinct from T cells, and CAR constructs optimised for their activation and persistence are essential.</p>



<p>“By combining validated methods for CAR designs with our myeloid-selective LNP platform, we are building a differentiated and highly integrated approach to in vivo cell therapy.”</p><div id="slot-two"></div>



<p>Liberate Bio CEO Shawn Davis said: “In vivo CAR-M represents a new chapter in immune reprogramming. By uniting best-in-class delivery with optimised myeloid CAR designs, we are establishing a durable foundation for a scalable and potentially safer alternative to CAR-T — one capable of reaching broader patient populations across autoimmune and oncology indications.”</p>



<p>The company intends to progress its initial in vivo CAR-M candidate into investigational new drug (IND)-enabling studies, targeting initial clinical evaluation via an investigator-initiated trial in the latter half of 2026.</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>

IBBQ

SBIO

CARM

<p>Liberate Bio has secured exclusive and non-exclusive licenses for patents on CAR designs specific to myeloid cells, enhancing its in vivo CAR-M therapies. The licenses, obtained from Carisma Therapeutics and the University of Pennsylvania, include engineered methods for monocytes and macrophages. The company aims to advance its CAR-M candidate into clinical trials by late 2026, leveraging its lipid nanoparticle technology for targeted immune cell programming.</p>

Liberate Bio gains licences for myeloid-specific CAR design patents